{"id":295560,"date":"2023-08-14T00:00:00","date_gmt":"2023-08-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0015-2023-biopharma-multiple-myeloma-current-treatment-treatment-sequencing-multiple-myeloma\/"},"modified":"2026-03-31T10:32:25","modified_gmt":"2026-03-31T10:32:25","slug":"trsqon0015-2023-biopharma-multiple-myeloma-current-treatment-treatment-sequencing-multiple-myeloma-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0015-2023-biopharma-multiple-myeloma-current-treatment-treatment-sequencing-multiple-myeloma-us\/","title":{"rendered":"Multiple Myeloma &#8211; Current Treatment &#8211; Treatment Sequencing &#8211; Multiple Myeloma (US)"},"content":{"rendered":"<p><strong>Key benefits and uses<\/strong><\/p>\n<p><strong>Pinpoint<\/strong> current drug positioning and uptake in one snapshot to facilitate forecasting.<\/p>\n<p><strong>Drill down<\/strong> into physicians\u2019 treatment sequences and understand who to position against or how to defend share.<\/p>\n<p><strong>Identify<\/strong> untapped treatment scenarios and key competitors to aid trial design.<\/p>\n<p><strong>Evaluate<\/strong> unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.<\/p>\n<p><strong>Discover<\/strong> untapped populations to expand product share and drive strategic decisions.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Where is my product positioned versus competitors in the treatment journey?<\/li>\n<li>What are physicians\u2019 most frequent treatment sequences? Who is benefiting, and how can I defend my asset\u2019s share and position?<\/li>\n<li>What are the market-relevant treatment scenarios according to oncology experts?<\/li>\n<li>Where are the untapped business opportunities on which I can capitalize?<\/li>\n<li>How can I optimize trial design and ensure a competitive edge for my pipeline asset?<\/li>\n<\/ul>\n<p><strong>GEOGRAPHY<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>PRIMARY MARKET RESEARCH<\/strong><\/p>\n<p class=\"text-align-left\">Survey of 102 U.S. hematologist-oncologists<\/p>\n<p><strong>Product <\/strong><strong>description<\/strong><\/p>\n<p>Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts\u2019 assumptions.<\/p>\n","protected":false},"template":"","class_list":["post-295560","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-multiple-myeloma","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295560\/revisions"}],"predecessor-version":[{"id":295790,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295560\/revisions\/295790"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}